Rheumatology Xagena

Medical Meeting
Xagena Mappa

Search results for "Belimumab"

Treatment with Belimumab ( Benlysta ) resulted in a sustained improvement of systemic lupus erythematosus ( SLE or lupus ) disease activity in 46% of patients at week 52.Historically, it has been diff ...

Patients with systemic lupus erythematosus ( SLE ) are at risk of irreversible damage across multiple organ systems because of both active disease and medication toxicities. The severity and freque ...

In 2016, the National Institute for Health and Care Excellence ( NICE ) approved the use of Belimumab ( Benlysta ) for the treatment of autoantibody-positive systemic lupus erythematosus ( SLE ). I ...